LBRX · LB Pharmaceuticals Inc Common Stock
View on chartInsiders & Stakes
| Pontifax Management 4 G.P. (2015) Ltd. 10% Owner | ▲ Buy | Open Market | 1,411,681 Shares held | 9/12/2025 | View profile |
| Ran Nussbaum Director | ▲ Buy | Open Market | 1,411,681 Shares held | 9/12/2025 | View profile |
| Deep Track Biotechnology Master Fund, Ltd. | ▲ Buy | Open Market | 666,666 Shares held | 9/12/2025 | View profile |
| Vida Ventures GP III, L.L.C. | ▲ Buy | Open Market | 2,029 Shares held | 9/12/2025 | View profile |
Transaction History
| Deep Track Biotechnology Master Fund, Ltd. | ▲ Buy | Open Market | 2,000,000 | $30.0M | 9/12/2025 |
| Deep Track Biotechnology Master Fund, Ltd. | ▲ Buy | Open Market | 666,666 | $10.0M | 9/12/2025 |
| Pontifax Management 4 G.P. (2015) Ltd. | ▲ Buy | Open Market | 1,000,000 | $15.0M | 9/12/2025 |
| Pontifax Management 4 G.P. (2015) Ltd. | ▼ Sell | Other | 411,681 | — | 9/12/2025 |
| Ran Nussbaum | ▼ Sell | Other | 411,681 | — | 9/12/2025 |
| Deep Track Biotechnology Master Fund, Ltd. | ▼ Sell | Other | 686,138 | — | 9/12/2025 |
| Ran Nussbaum | ▲ Buy | Open Market | 1,000,000 | $15.0M | 9/12/2025 |
| Vida Ventures GP III, L.L.C. | ▼ Sell | Other | 547,648 | — | 9/12/2025 |
| Vida Ventures GP III, L.L.C. | ▼ Sell | Other | 1,262 | — | 9/12/2025 |
| Vida Ventures GP III, L.L.C. | ▲ Buy | Open Market | 332,566 | $5.0M | 9/12/2025 |
| Vida Ventures GP III, L.L.C. | ▲ Buy | Open Market | 767 | $12K | 9/12/2025 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
LBRX News: Fair Value Rises, New Preclinical Data, and Analyst Coverage
LBRX has seen its fair value rise after the company shifted its outlook for LB‑102. The firm also presented new preclinical data supporting the drug’s bimodal mechanism at the ECNP Congress, while continuing late‑stage clinical programs. In addition, Canaccord Genuity added coverage with a price target of $65.
LBRX News: Fair Value Rises, New Preclinical Data, and Analyst Coverage. LBRX has seen its fair value rise after the company shifted its outlook for LB‑102. The firm also presented new preclinical data supporting the drug’s bimodal mechanism at the ECNP Congress, while continuing late‑stage clinical programs. In addition, Canaccord Genuity added coverage with a price target of $65.